IBI188 Combination Therapy in Solid Tumors

Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Study ID
NCT04861948
Phase
PHASE1
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
12 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • IBI188 — DRUG
    intravenous
  • GM-CSF — DRUG
    subcutaneous injection
  • Cisplatin/Carboplatin — DRUG
    intravenous
  • Bevacizumab — DRUG
    intravenous
  • Sintilimab — DRUG
    intravenous
  • Pemetrexed — DRUG
    intravenous

Study Details

A Phase Ib study aim to evaluate the efficacy, safety, and tolerability of IBI188 combination therapy in subjects with advanced malignancies

Key Dates

First listed
Apr 27, 2021
Start date
May 25, 2021
Status verified
Oct 2022
Primary completion
Jul 30, 2022
Completion
Jul 30, 2022

Study Design

Enrollment
9 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Cohort A
  • Experimental: Cohort B
  • Experimental: Cohort C
  • Experimental: Cohort D

Primary Outcome Measure

Objective Response Rate [ Time Frame: 24 months ]

Related Studies